Selectin inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 6, 2010, Pages 781-793

  Bedard, Patricia W ^a   Kaila, Neelu ^a  

^a PFIZER INC   (United States)

Author keywords

Adhesion molecules; Inflammation; Selectins; Vascular disease

Indexed keywords

ABC 48; AP 12009; BIMOSIAMOSE; CYCLOHEXANE DERIVATIVE; FLAVONOID; GALLIC ACID; GMI 1070; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY EL246; PGX 100; PHENOXODIOL; PLACEBO; PSI 421; PSI 697; PURINE DERIVATIVE; RECOMBINANT ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; RECOMBINANT PROTEIN; SELECTIN ANTAGONIST; SULFONIC ACID DERIVATIVE; THIENO[3,2 C]PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ASTHMA; ATHEROSCLEROSIS; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG STRUCTURE; GRAFT REJECTION; HEART MUSCLE ISCHEMIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLAMMATORY DISEASE; MALIGNANT NEOPLASTIC DISEASE; NEUTROPHILIA; NONHUMAN; PATENT; PAW EDEMA; PERITONITIS; PSORIASIS; REPERFUSION INJURY; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESTENOSIS; REVIEW; SECONDARY PREVENTION; SICKLE CELL ANEMIA; VASCULITIS; VEIN THROMBOSIS;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMMUNE SYSTEM; INFLAMMATION; LIGANDS; PATENTS AS TOPIC; SELECTINS;

EID: 77952569435     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543771003767468     Document Type: Review

References (87)

1. Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008;111(11):5271-5281
2. Kaila N, Somers WS, Thomas BE, et al. Quinic acid derivatives as sialyl Lewis(x)-mimicking selectin inhibitors: design, synthesis, and crystal structure in complex with E-selectin. J Med Chem 2005;48(13):4346-4357
3. Somers WS, Tang J, Shaw GD, Camphausen RT. Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of Pand E-selectin bound to sLex and PSGL-1. Cell 2000;103(3):467-479
4. Leppänen A, Yago T, Otto VI, et al. Model glycosulfopeptides from P-selectin glycoprotein ligand-1 require tyrosine sulfation and a core 2-branched O-glycan to bind to l-selectin. J Biol Chem 2003;278(29):26391-26400
5. Frennette PS, Wagner DD. Insights into selectin function from knockout mice. Thromb Haemost 1997;78(1):60-64
6. Ludwig RJ, Sch€on MP, Boehncke W-H. P-selectin. Expert Opin Ther Targets 2007;11(8):1103-1117
7. Rossi B, Constantin G. Anti-selectin therapy for the treatment of inflammatory diseases. Inflamm Allergy Drug Targets 2008;7(2):85-93
8. Boehncke W-H, Sch€on MP. Interfering with leukocyte rolling -- a promising therapeutic approach in inflammatory skin disorders? Trends Pharmacol Sci 2003;24(2):49-52
9. Kaila N, Thomas BE. Selectin inhibitors. Expert Opin Ther Patents 2003;13(3):305-317
10. Regents of the University of California. Heparin compositions and selectin inhibition. WO2007014049; 2007
11. Stevenson JL, Varki A, Borsig L. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res 2007;120(Suppl 2):S107-S11
12. Hostettler N, Naggi A, Torri G, et al. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J 2007;21(13):3562-3572
13. Ludwig RJ. Therapeutic use of heparin beyond anticoagulation. Cur Drug Discov Technol 2009;6:281-289
14. Min W, Yanguang G, Meihong T, et al. Selectively desulfated heparin inhibits P-selectin-mediated adhesion of human melanoma cells. Cancer Lett 2005;229(1):123-126
15. Adis R&D Insight Database. PGX 100. Wolters Kluwer Health; 2009
16. ParinGenix. A study designed to evaluate ODSH in subjects with exacerbations of COPD. National Institutes of Health; 2009
17. GlycoMimetics, Inc. Glycomimetic antagonists for both E-and P-selectins. WO2005054264; 2005
18. GlycoMimetics, Inc. Specific antagonist for both E-and P-selectins. WO2005051920; 2005
19. GlychoTech, Inc. Compounds and methods for inhibiting selectin-mediated function. WO2003097658; 2003
20. GlycoMimetics, Inc. Heterobifunctional pan-selectin inhibitors. WO2007028050; 2007
21. GlycoMimetics, Inc. Glycomimetic replacements for hexoses and N-acetyl hexosamines. US20080161546; 2008
22. GlycoMimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and N-acetyl hexosamines. US20080200406; 2008
23. ClinicalTrials.gov. Study of intravenous GMI-1070 in adults with sickle cell disease. NIH; 2009
24. Chang J, Patton J, Sarkar A, et al. A novel selectin antagonist, GMI-1070, prevents vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and activation. 49th Annual Meeting; American Society of Hematology. Blood 2007;110(11):2245
25. Texas Biotechnology Corp. Di-and trivalent small molecule selectin inhibitors. WO1997001335; 1999
26. Beeh K, Beier J, Meyer M, et al. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm Pharmacol Ther 2006;19(4):233-241
27. Friedrich M, Bock D, Philipp S, et al. Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch Dermatol Res 2006;297(8):345-351
28. ClinicalTrials.gov. Safety and efficacy study of bimosiamose cream to treat psoriasis. NIH; 2009
29. ClinicalTrials.gov. Study to evaluate the effect of bimosiamose on ozone induced sputum neutrophilia. NIH; 2009
30. Revotar Biopharmaceuticals AG. Crystalline forms of 1,6-bis [3-(3- carboxymethylphenyl)-4-(2-alpha-dmannopyranosyl- oxy)-phenyl] hexane. WO2008028966; 2008
31. Revotar Biopharmaceuticals AG. Use of 1,6-bis [3-(3-carboxymethylphenyl)- 4-(2- alpha-d-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions. WO2008028950; 2008
32. Revotar Biopharmaceuticals AG. Pharmaceutical composition for the treatment of IL-8 mediated diseases. WO2008098985; 2008
33. Malhotra R, Ward M, Bright H, et al. Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells. Microbes Infect 2003;5(2):123-133
34. Insight. ARD. Bimosiamose; 2009
35. Taisho Pharma Co., Ltd. Persulfated oligosaccharide acting on selectins and chemokine. WO2004011662; 2006
36. Revotar Biopharmaceuticals AG. Novel phloroglucinol derivatives having selectin ligand activity. WO2007039112; 2007
37. Revotar Biopharmaceuticals AG. Non-glycosylated/non-glycosidic/ non-peptidic small molecule PSGL-1 mimetics for the treatment of inflammatory disorders. WO2005090284; 2005
38. Revotar Biopharmaceuticals AG. Novel multi-cyclic compounds. WO2007039111; 2007
39. Revotar Biopharmaceuticals AG. Novel aromatic compounds and their use in medical applications. WO2007039113; 2007
40. Revotar Biopharmaceuticals AG. Novel nitrocatechol derivatives having selectin ligand activity. WO2007039114; 2007
41. Wyeth Corp. Methods and compositions for selectin inhibition. WO2005047258; 2005
42. Wyeth Corp. Methods and compositions for selectin inhibition. WO2005047257; 2005
43. Bedard PW, Clerin V, Sushkova N, et al. Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10- tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J Pharmacol Exp Ther 2008;324(2):497-506
44. Kaila N, Janz K, Huang A, et al. 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10- tetrahydrobenzo[h]quinoline-4-carboxylic acid (PSI-697): identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists. J Med Chem 2006;50(1):40-64
45. Clerin V, Resmini C, Wong T, et al. WAY-197697, a P-selectin antagonist, reduces atherosclerosis in apolipoprotein E deficient mice. Intern Soc Thromb Haemost Meeting. J Thromb Haemost 2005;3(Suppl 1):abstract P2355
46. Myers DD Jr, Henke PK, Bedard PW, et al. Treatment with an oral small molecule inhibitor of P-selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc Surg 2006;44(3):625-632
47. Myers DD Jr, Wrobleski S, Longo C, et al. Resolution of venous thrombosis using a novel oral small-molecule inhibitor of P-selectin (PSI-697) without anticoagulation. J Thromb Haemost 2007;97(3):400-407
48. Chelliah R, Lucking AJ, Tattersall L, et al. P-selectin antagonism reduces thrombus formation in humans. J Thromb Haemost 2009;11:1915-1919
49. Wyeth Corp. Methods and compositions for selectin inhibition. WO2008121805; 2008
50. Wyeth Corp. Methods and compositions for selectin inhibition and quinoline derivatives and pharmaceutical compositions comprising them for selectin inhibition. WO2008121817; 2008
51. Meier T, Myers DD Jr, Wrobleski S, et al. Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation. J Thromb Haemost 2008;99(2):343-351
52. Rimonyx Pharmaceuticals Ltd. Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof. WO2004069149; 2008
53. University of Mainz Johannes Gutenberg. Non-glycosidic and non-peptidic selectin inhibitors, and the use thereof. WO2006010598; 2006
54. Astellas Pharma, Inc (Yamanouchi Pharma). P-selectin targeting ligand and compositions there of WO2004105783; 2007
55. Astellas Pharma, Inc (Yamanouchi Pharma Co LTD). Polyhydroxy phenols and their use in binding P-selectin. WO2004105740; 2007
56. Astellas Pharma Europ BV. Compounds binding to P-selectin. WO2004018502; 2009
57. Astellas Pharma Europ BV (Yamanouchi Europ BV). Glucose-based compounds with affinity to P-selectin. WO2004033473; 2007
58. Freie Uni Berlin; Charité Universitaetsmedizin. Dendritic polyglycerol sulfates and sulfonates and their use for inflammatory diseases. WO2008015015; 2008
59. Genetics Institute LLC; Temple University. Modulation of leukocyte-endothelial interactions following ischemia. US20030083258; 2003
60. Gaber AO, Moore LW, Mulgaonkar S, et al. YSPSL (rPSGL-Ig) for the prevention of delayed graft function (DGF): Results of double-blind, placebo-controlled, multi-center phase I/II safety and efficacy study: 832. Transplantation 2008;86(2):290
61. ClinicalTrials.gov. YSPSL for prevention of ischemic reperfusion injury in patients undergoing cadaveric orthotopic liver transplantation. NIH; 2009
62. Amersi F, Farmer DG, Shaw GD, et al. P-selectin glycoprotein ligand-1 (rPSGLIg)- mediated blockade of CD62 selectin molecules protects rat steatotic liver grafts from ischemia/reperfusion injury. Am J Transplant 2002;2(7):600-608
63. Chen Y, Ruetzler C, Pandipati S, et al. Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci USA 2003;100(25):15107-15112
64. Reuters. Novavax inc (nvax.O) company profile. 2009. Available from: http://www. reuters.com/finance/stocks/companyProfile? rpc=66&symbol=NVAX.O. [Cited 28 October 2009]
65. PJB Pharmaprojects PRDPI. CY-1787. Informa; 2009
66. Aeres Biomedical Ltd. Antibodies to P-selectin and their uses. EP642356; 2003
67. Ligocyte Pharmaceuticals, Inc.; Univ Montana. Methods for the treatment and prevention of infection using anti-selectin agents. WO2006083322; 2006
68. Jutila M, Watts G, Walcheck B, Kansas G. Characterization of a functionally important and evolutionarily well-conserved epitope mapped to the short consensus repeats of E-selectin and L-selectin. J Exp Med 1992;175(6):1565-1573
69. Hoffmann La Roche, Inc. Anti-P-selectin antibodies. US20050226876; 2005
70. Selexys Pharmaceuticals Corp. Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases. WO2008069999; 2008
71. Jenison R, Jennings S, Walker D, et al. Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion. Antisense Nucleic Acid Drug Dev 1998;8(4):265-279
72. IMS R&D Focus. Aptamers targeted to P-selectin and to L-selectin for the treatment of inflammatory disorders,. IMS Health Global Services; 2003
73. IMS R&D Focus. Aptamer P-selectin inhibitor for the potential treatment of sickle cell disease. IMS Health Global Services; 2008
74. Archemix Corp. Nucleic acid ligand to B. anthracis protective antigen. WO2004085665; 2004
75. Eisai Co., Ltd. Deazapurines and uses thereof. US7314936; 2008
76. Eisai Co., Ltd. Novel deazapurines and uses thereof. WO2004063336; 2004
77. Eisai Co., Ltd. Deazapurines and uses thereof. WO2003057696; 2003
78. Novogen Research PTY LTD. Treatment of restenosis. US20050119301; 2005
79. Saif MW, Tytler E, Lansigan F, et al. Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment ofpancreaticobiliary cancers. Exp Opin Investig Drugs 2009;18(4):469-479
80. Eberhard Karls University. Sirna molecules for the treatment of blood vessels. WO2006077112; 2008
81. Walker T, Wendel HP, Tetzloff L, et al. Inhibition of adhesion molecule expression on human venous endothelial cells by non-viral siRNA transfection. J Cell Mol Med 2007;11(1):139-147
82. Antisense Pharma GmbH. Pharmaceutical composition. WO2005084712; 2005
83. Schlingensiepen K, Fischer-Blass B, Schmaus S, Ludwig S. Antisense therapeutics for tumor treatment: The TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res 2008;177:137-150
84. Gardiner EE, De Luca M, McNally T, et al. Regulation of P-selectin binding to the neutrophil P-selectin counter-receptor P-selectin glycoprotein ligand-1 by neutrophil elastase and cathepsin G. Blood 2001;98(5):1440-1447
85. Ward CM, Vinogradov DV, Andrews RK, Berndt MC. Characterization of mocarhagin, a cobra venom metalloproteinase from Naja mocambique mocambique, and related proteins from other Elapidae venoms. Toxicon 1996;34(10):1203-1206
86. Genetics Institute. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof. US6413760; 2002
87. Barbas A, White R. The development and testing of aptamers for cancer. Cur Opin Investig Drugs 2009;10(6):572-578